scispace - formally typeset
M

Michael Buckstein

Researcher at University of Pennsylvania

Publications -  22
Citations -  2046

Michael Buckstein is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications receiving 1502 citations.

Papers
More filters
Journal ArticleDOI

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA

TL;DR: It is concluded that nucleoside modifications suppress the potential of RNA to activate DCs, and the innate immune system may detect RNA lacking nucleosides modification as a means of selectively responding to bacteria or necrotic tissue.
Journal ArticleDOI

Characterization of nucleotide pools as a function of physiological state in Escherichia coli.

TL;DR: dTTP is the most abundant deoxynucleoside triphosphate (dNTP) in the cell despite the fact that its precursors, UDP and UTP, are not; all dNTPs decrease through the growth curve but do not have the abrupt drop, as seen with other nucleotides when the cells transition into stationary phase.
Journal ArticleDOI

Functional regulation of the opposing (p)ppGpp synthetase/hydrolase activities of RelMtb from Mycobacterium tuberculosis.

TL;DR: This study purified and characterized fragments of the 738-amino acid Rel(Mtb) protein and confirmed the hypothesis that amino acid fragment 1-394 contains both synthesis and hydrolysis activities, amino acids fragment 87-394 containing only (p)ppGpp synthesis activity, and amino acid fragments 1-181 contains only ( p)pp Gpp hydrolytic activity.
Journal ArticleDOI

Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

TL;DR: In this article , a paradigm shift in trial design, specimen collection and analysis is proposed for window-of-opportunity trials, during which patients receive short-duration pre-surgical therapies, provide a platform for understanding the therapies' mechanisms of action.
Journal ArticleDOI

Combination TACE and SBRT for Unresectable Single Large HCC: Results from a Prospective Phase II Trial.

TL;DR: In this paper , a phase 2 trial showed very promising ORR when combining transarterial chemoembolization (TACE) and stereotactic body radiation therapy (SBRT) for BCLC A patients with a solitary HCC from 4 to 7 cm.